MarketVIEW - Staphylococcus aureus vaccines

  • April 2012
  • -
  • VacZine Analytics Group Of Assay Advantage Ltd

Gram-positive Staphylococcus aureus is an opportunistic pathogen and a major cause of patient morbidity and mortality, especially in "at risk" populations. The organism can cause a wide range of infections ranging from mild skin infections to life-threatening bloodstream infections and pneumonia.

Prophylatic vaccines could prevent S.aureus infections and become cost effective in achieving savings from expensive infection control interventions e.g. MRSA screening on admission. Although all major companies have now announced S.aureus vaccine programs, Pfizer (SA4Ag) are the most advanced now the Merck & Co (Intercell AG) candidate, V710 has been terminated.

This MarketVIEW product gives a comprehensive vaccine value ($USD/volume (000s) forecast for all products within target nosocomial populations until 2030. The model includes LO/BASE/HI forecast scenarios so the user can visualize the commercial impact of differing targetting/competitive and pricing scenarios. This product is an essential component of any commercial opportunistic assessment focused on nosocomial vaccines.

THIS PRODUCT IS A SUMMARY PRESENTATION + MODEL

Table Of Contents

Contents - Summary presentation (MS PowerPoint based)

Author’s note
Contents
Executive Summary
Commercial model - key outputs
Total global available market ($000s all scenarios), pricing level 1
Total global available market ($000s all scenarios), pricing level 2
Total global available market ($000s all scenarios), pricing level 3
Total predicted demand (doses 000s all scenarios)
Total available volume per vaccine segment, US - 2025
Model forecast comparisons: March 2010 v current (April 2012) - volume/value
Model forecast comparisons: March 2010 v current (April 2012) - per segment
Company revenue summary
Modelling commercial potential
The role of S.aureus vaccine
Characteristics of the ideal S.aureus vaccine
S.aureus vaccine: target product profile (minimum)
S.aureus vaccine: target product profile (ideal)
Target populations: vaccination strategies
Vaccine target populations: overview
Vaccine target populations: scenario definition
Markets included in model
Commercial model assumptions: general
Commercial model assumptions: short-term risk
Commercial model assumptions: chronic risk
Model forecast assumptions: comparing March 2010 with current (April 2012)
Notes on Pricing
S.aureus vaccines: RandD pipeline
Competitor landscape overview
S.aureus vaccine: estimated launch dates
Pfizer: SA4Ag - background
Pfizer: SA4Ag - Phase I data
GSK: GSK2392103A/Nabi
Other vaccine candidates
Merck and Co/Intercell AG - V710
Staphylococcus aureus: update on infection control
Situation overview: MRSA infection control
US situation
Review of latest epidemiology
Acute care hospitals: US
Acute care hospitals: pan-European
Acute care hospitals: UK
Acute care hospitals: Germany
Acute care hospitals: France
Europe: methicillin-resistance disease trends
MRSA: colonization rates
Backup material: methodology
Methodology: general comments - CABG, ESRD and LTCFs
Methodology: general comments - ICU/elective
Methodology: general comments - diabetics
Bibliography
Disclaimer
About VacZine Analytics

PAGES: 80 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

Contents - Vaccine demand model (MS Excel-based)

Title sheet
TOTAL CHARTS - forecast to 2030
CHARTS VALUE - pricing level 1
CHARTS VALUE - pricing level 2
CHARTS VALUE - pricing level 3
CHARTS VOLUME - HIGH
VALUE SUMMARY - pricing level 1
VALUE SUMMARY - pricing level 2
VALUE SUMMARY - pricing level 3
Competitor summary (Base scenario)
US (all scenarios LO/BASE/HIGH)
Canada
UK
Germany
France
Spain
Italy
EU - other
Australia
Japan
Country target populations - forecast to 2030
Source material
LTCFs
CABG
Orthopaedic
ESRD
Hospital admissions
Elective admissions
Diabetes
US segments
Back page
About VacZine Analytics
Disclaimer

WORKSHEETS: ~65

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • August 2014
  • by Global Data

PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023 Summary Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented ...

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update

  • $ 10 995
  • Industry report
  • September 2014
  • by Global Data

PharmaPoint: Ulcerative Colitis - Global Drug Forecast and Market Analysis to 2022 - Event-Driven Update Summary During the forecast period from 2012-2022, the growth of the UC market will be driven largely ...

Cancer Vaccines: Technologies and Global Markets

Cancer Vaccines: Technologies and Global Markets

  • $ 6 650
  • Industry report
  • Dec 2014
  • by BCC Research

REPORT HIGHLIGHTS The global market for cancer vaccines was about $4.5 billion in 2013. This market reached about $4.0 billion in 2014 and is expected to reach $4.3 billion in 2019, registering a compound ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.